Vistin Pharma ASA (OSL:VISTN)
Norway · Delayed Price · Currency is NOK 19.35
+0.15 (0.78%)
At close: Nov 13, 2026
Vistin Pharma ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 431.55 | 452.29 | 429.09 | 435.39 | 287.68 | 275.81 |
Other Revenue | - | - | 0.41 | 2.94 | 17.18 | 2.81 |
| 431.55 | 452.29 | 429.5 | 438.33 | 304.85 | 278.62 | |
Revenue Growth | -5.20% | 5.31% | -2.01% | 43.78% | 9.41% | 9.74% |
Cost of Revenue | 152.06 | 151.51 | 149.97 | 176.64 | 138.06 | 96.1 |
Gross Profit | 279.49 | 300.78 | 279.53 | 261.68 | 166.79 | 182.53 |
Selling, General & Admin | 82.08 | 86.17 | 81.72 | 81.84 | 69.73 | 64.96 |
Other Operating Expenses | 102.83 | 99.73 | 93.49 | 93.9 | 90.88 | 73.71 |
Operating Expenses | 208.13 | 208.43 | 194.24 | 193.09 | 172.88 | 149.28 |
Operating Income | 71.36 | 92.35 | 85.3 | 68.6 | -6.1 | 33.25 |
Interest Expense | -5.43 | -1.96 | -2.34 | -2.27 | -2.14 | -0.36 |
Interest & Investment Income | 8.33 | 0.4 | 0.51 | 0.22 | 0.03 | 0.27 |
Currency Exchange Gain (Loss) | 5.01 | 5.01 | -3.05 | -7.92 | 2.51 | -1.13 |
Other Non Operating Income (Expenses) | 0.04 | 0.04 | 0.04 | -0.11 | -0.31 | -0.03 |
EBT Excluding Unusual Items | 79.31 | 95.84 | 80.45 | 58.52 | -6.01 | 32 |
Pretax Income | 79.31 | 95.84 | 80.45 | 58.52 | -6.01 | 32 |
Income Tax Expense | 16.68 | 21.09 | 17.7 | 12.92 | -1.29 | 7.13 |
Earnings From Continuing Operations | 62.63 | 74.75 | 62.75 | 45.6 | -4.72 | 24.87 |
Net Income | 62.63 | 74.75 | 62.75 | 45.6 | -4.72 | 24.87 |
Net Income to Common | 62.63 | 74.75 | 62.75 | 45.6 | -4.72 | 24.87 |
Net Income Growth | -19.77% | 19.13% | 37.62% | - | - | - |
Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 | 44 |
Shares Outstanding (Diluted) | 44 | 44 | 44 | 44 | 44 | 44 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | 1.41 | 1.69 | 1.42 | 1.03 | -0.11 | 0.56 |
EPS (Diluted) | 1.41 | 1.69 | 1.42 | 1.03 | -0.11 | 0.56 |
EPS Growth | -19.77% | 19.13% | 37.62% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 85.8 | 61.35 | 67.05 | 72.69 | -74.8 | -18.26 |
Free Cash Flow Per Share | 1.94 | 1.38 | 1.51 | 1.64 | -1.69 | -0.41 |
Dividend Per Share | 1.500 | 1.500 | 1.250 | 1.000 | 0.750 | 0.750 |
Dividend Growth | 20.00% | 20.00% | 25.00% | 33.33% | 0% | 50.00% |
Gross Margin | 64.77% | 66.50% | 65.08% | 59.70% | 54.71% | 65.51% |
Operating Margin | 16.54% | 20.42% | 19.86% | 15.65% | -2.00% | 11.93% |
Profit Margin | 14.51% | 16.53% | 14.61% | 10.40% | -1.55% | 8.92% |
Free Cash Flow Margin | 19.88% | 13.56% | 15.61% | 16.58% | -24.54% | -6.55% |
EBITDA | 93.65 | 113.95 | 103.27 | 84.89 | 5.33 | 42.79 |
EBITDA Margin | 21.70% | 25.19% | 24.04% | 19.37% | 1.75% | 15.36% |
D&A For EBITDA | 22.28 | 21.6 | 17.97 | 16.3 | 11.43 | 9.54 |
EBIT | 71.36 | 92.35 | 85.3 | 68.6 | -6.1 | 33.25 |
EBIT Margin | 16.54% | 20.42% | 19.86% | 15.65% | -2.00% | 11.93% |
Effective Tax Rate | 21.03% | 22.00% | 22.00% | 22.08% | - | 22.28% |
Revenue as Reported | 452.29 | 452.29 | 429.5 | 438.33 | 304.85 | 278.62 |